The fortuitous results of experiments showing a higher incidence of tumors after the administration of 125I than after 131I, raised the question of the relative biological effectiveness of 125I. A reevaluation of the microdosimetry of 125I in the thyroid follicle revealed that due to the low energy electrons–especially the Auger electrons–the radiation dose delivered to the cell colloid interface is ca. 4 or more times greater than that from an equivalent amount of 131I. At the same time, the nucleus dose of the cell is reduced by up to 80% as compared to that of 1311. 125I was therefore suggested as a suitable substitute for the treatment of thyrotoxicosis. On the basis of the radiation dose delivered to the nucleus, a dose of 40 mCi on the average was proposed. On the other hand, basing the dose on the radiation delivered to the colloid-cell boundary, which is probably the site of the sensitive hormonogenic mechanism, much smaller amounts, in the range of 2–3.5 mCi 125I were administered. The results obtained in this series of 35 patients, with a follow-up of up to a year have so far partially justified this approach. A 20% failure was noted which suggests the use of carefully adjusted higher doses, most probably in the range of 4–6 mCi.

Keywords:
Iodine-125, Thyrotoxicosis, Treatment, Microdosimetry
This content is only available via PDF.
© 1971 S. Karger AG, Basel
1971
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.